Clinical trial · no report yet · Phase 1/Phase 2
IDeate-Lung03
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- NCT06362252 ↗
- Recruiting
- Daiichi Sankyo
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination With Atezolizumab With or Without Carboplatin as First-line Induction or Maintenance, in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan; Atezolizumab; Carboplatin
- Arms
- Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg) · Experimental
- Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg) · Experimental
- Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg) · Experimental
- Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg) · Experimental
- Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg) · Experimental
- Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg) · Experimental
- Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg) · Experimental
- Enrollment
- 123 (estimated)
- Primary outcomes
- Number of Participants Reporting Dose-limiting Toxicities Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A)
- Overall Number of Participants With Treatment-emergent Adverse Events Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
- Sponsor
- Daiichi Sankyo with Merck Sharp & Dohme LLC
- Start
- Jul 22, 2024
- Primary completion
- Jul 20, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06362252 · updated Oct 1, 2026